C=o In A C(=o)o Group (e.g., Nicotinic Acid, Etc.) Patents (Class 514/356)
  • Patent number: 11058672
    Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: July 13, 2021
    Assignee: CHIESI FARMACEUTICA S.P.A.
    Inventors: Rajeshwar Motheram, Gopal Krishna, Min Ding, Keith Flood, Kornepati Ramakrishna
  • Patent number: 11013705
    Abstract: Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include BHB, analogs thereof, and GPR109A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions.
    Type: Grant
    Filed: March 14, 2020
    Date of Patent: May 25, 2021
    Assignees: The Regents of the University of California, Augusta University Research Institute
    Inventors: Thomas Weimbs, Jacob Torres, Muthusamy Thangaraju
  • Patent number: 10973791
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: April 13, 2021
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10959991
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: March 30, 2021
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Patent number: 10952998
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: March 23, 2021
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Patent number: 10925965
    Abstract: The invention relates to the discovery that the addition of aromatic carboxylate ions inhibit protein instability caused by aromatic preservatives. Thus, the invention relates to compositions, preferably aqueous compositions, comprising a protein, an aromatic preservative and aromatic carboxylate ions. The proteins remain stable and suitable for storage at ambient temperatures or lower, even in aqueous form. Preferably, the aqueous composition comprises a protein, a phenolic preservative and benzoate ions, wherein the pH of the composition is at least 1 unit greater than the pKa of benzoic acid. The invention also provides methods of reducing protein degradation by aromatic preservatives in an aqueous formulation of a protein susceptible to such degradation, comprising the step of adding aromatic carboxylate ions to the formulation wherein the formulation is maintained at a pH that is at least 1 unit greater than the pKa of the corresponding aromatic carboxylic acid.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: February 23, 2021
    Assignee: Arecor Limited
    Inventors: Jan Jezek, Barry Kingston Derham
  • Patent number: 10894039
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: January 19, 2021
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Patent number: 10881645
    Abstract: Methods for controlling, maintaining, or reducing blood pressure, and/or for treating, preventing, or alleviating symptoms such as dyspnea, in a patient suffering from or susceptible to acute heart failure. The methods involve the administration of an effective amount of a pharmaceutical composition comprising a short acting dihydropyridine compound such as clevidipine. The pharmaceutical composition may be administered at an initial dose, and if blood pressure is not controlled or maintained within a target blood pressure range or reduced to within a target blood pressure range, the initial dose may be titrated to achieve a blood pressure within the target blood pressure range. The patient may have a systolic blood pressure of about 120 mmHg or above.
    Type: Grant
    Filed: October 26, 2013
    Date of Patent: January 5, 2021
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Edward C. Spindler, Jr., Loretta M. Itri, Gregory Williams, Ming-yi Hu
  • Patent number: 10857117
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: December 8, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10842764
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: November 24, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10806713
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: October 20, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10799453
    Abstract: Provided herein are stable amlodipine liquid formulations. Also provided herein are methods of using amlodipine liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: October 13, 2020
    Assignee: Silvergate Pharmaceuticals, Inc.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Patent number: 10718782
    Abstract: The present invention relates to a method of evaluating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator in a harvested skin sample, and a method of evaluating a drug for improving, preventing or treating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator in cultured cells.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: July 21, 2020
    Assignees: Shiseido Company, Ltd., ETH Zurich
    Inventors: Yuzo Yoshida, Kentaro Kajiya, Michael Detmar
  • Patent number: 10702489
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: July 7, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10695329
    Abstract: Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: June 30, 2020
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Scott Brauer, Gerold L. Mosher
  • Patent number: 10660789
    Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder medi
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: May 26, 2020
    Assignee: RICHTER GEDEON NYRT.
    Inventors: Ferenc Fülöp, László Vígh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
  • Patent number: 10588881
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: March 17, 2020
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10485778
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 26, 2019
    Assignee: lo Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10414655
    Abstract: Stem cell, bone and nerve scaffolding comprising discrete carbon nanotubes is disclosed. The discrete carbon nanotubes may be have targeted, or selective oxidation levels and/or content on the interior and exterior of the tube walls. The described scaffolding may be used to guide, target and protect stem cells upon injection into the body.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: September 17, 2019
    Assignee: Molecular Rebar Design, LLC
    Inventors: Clive P. Bosnyak, Kurt W. Swogger, Nancy Henderson, Paul Everill
  • Patent number: 10034862
    Abstract: The present invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disorders containing losartan or a pharmaceutically acceptable salt thereof; amlodipine or a pharmaceutically acceptable salt thereof; a disintegrant; and a coating agent. The composition of the present invention, which has the best combination and optimum ratio of a disintegrant to a coating agent, shows sufficient strength and high dissolution rates under various pH environments, and thus, it is useful for the preparation of an excellent solid formulation exhibiting improved drug delivery efficiency and storage stability.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: July 31, 2018
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Leedong Roh, Ho Taek Im, Young Su Yoon, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
  • Patent number: 10010537
    Abstract: Pharmaceutical formulations comprising clevidipine and an antimicrobial agent exhibit a reduced propensity for microbial growth and provide increased convenience to health care workers administering clevidipine-containing formulations to patients.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: July 3, 2018
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Rajeshwar Motheram, Gregory Charles Williams
  • Patent number: 9968125
    Abstract: This invention relates to nicotine microparticles formulations made with the help of a diketopiperazine compound, in particular fumaryl diketopiperazine (FDKP). The invention relates to the various types of microparticles that can be made, in particular nicotine-coated and nicotine-loaded microparticles. The invention further relates to the various methods that can be used in making the microparticles. One particular method involves making FDKP microparticles which are further surface-coated with nicotine. Another particular method involves mixing nicotine with FDKP2? and/or FDKP and then forming microparticles which contain nicotine throughout their volume. The invention also relates to the use of this microparticles in tobacco related therapies, such as tobacco replacement or tobacco withdrawal.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: May 15, 2018
    Assignee: Philip Morris Products S.A.
    Inventors: Alex Stenzler, Noe Zamel, Arthur Slutsky, Steven Ellis
  • Patent number: 9933436
    Abstract: The present invention relates to a method of evaluating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator in a harvested skin sample, and a method of evaluating a drug for improving, preventing or treating cellulite using fibulin-3 and/or sarcoglycan gamma as an indicator in cultured cells.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: April 3, 2018
    Assignees: Shiseido Company, Ltd., ETH Zurich
    Inventors: Yuzo Yoshida, Kentaro Kajiya, Michael Detmar
  • Patent number: 9913886
    Abstract: The present invention provides an agent for the treatment or prophylaxis of arteriosclerosis comprising an expression vector encoding a chimeric Hepatitis B virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of apolipoprotein (a), wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis B virus core antigen polypeptide.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: March 13, 2018
    Assignee: AnGes, Inc.
    Inventors: Mariko Kyutoku, Hironori Nakagami, Hiroshi Koriyama, Futoshi Nakagami, Ryuichi Morishita
  • Patent number: 9827193
    Abstract: The present invention provides an inhalation-type pharmaceutical composition for hypertension and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising propranolol, captopril, amlodipine besylate, losartan, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: November 28, 2017
    Inventor: Hsin-Yung Lin
  • Patent number: 9778267
    Abstract: The invention provides methods for identifying modulators of ion channels without the use of recombinant cell lines over-expressing the ion channel proteins or the use of detection labels.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: October 3, 2017
    Assignee: X-Body, Inc.
    Inventors: Brant Binder, Lance Laing
  • Patent number: 9763919
    Abstract: Described herein is a new oral method for using MK-0677 for detecting growth hormone (GH) deficiency (GHD). Also described is a method of treating growth hormone (GH) deficiency (GHD) in children with a functional hypothalamic-pituitary GH axis.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: September 19, 2017
    Assignee: AMMONETT PHARMA, LLC
    Inventor: Michael Oliver Thorner
  • Patent number: 9737478
    Abstract: The invention contemplates compositions for the treatment of malaria comprising an anti-malaria drug and an adjuvant which promotes vasodilation and methods of using same.
    Type: Grant
    Filed: September 13, 2010
    Date of Patent: August 22, 2017
    Assignee: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), The United States of America NIH Division of Extramural Inventions and Technology Resources (DEITR)
    Inventors: Leonardo Jose de Moura Carvalho, Pedro Cabrales
  • Patent number: 9737524
    Abstract: Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: August 22, 2017
    Assignee: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION
    Inventors: Masafumi Ihara, Takakuni Maki, Akihiko Taguchi
  • Patent number: 9724314
    Abstract: This disclosure is directed to methods and compositions to inhibit MASP protein activity using small molecule inhibitors. In one aspect, the disclosure is directed to methods for identifying inhibitors of MASP protein activity, including methods of screening capable of inhibiting MASP protein activity.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: August 8, 2017
    Assignee: University of Leicester
    Inventors: Alexandre Gingras, Russell Wallis
  • Patent number: 9642845
    Abstract: The invention relates to the use of nicotinic acid alkyl esters, especially myristyl nicotinate, to inhibit side effects associated with retinoic acid therapy. Also a part of the invention is a method for improving skin cell differentiation by administering the nicotinic acid alkyl ester in an amount sufficient to increase expression of caspase 14 and filaggrin. Deficiencies in expression of these molecules can be treated in this way as well.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: May 9, 2017
    Assignee: University of Kentucky Research Foundation
    Inventors: Elaine L. Jacobson, Myron K. Jacobson, Russell Coyle, Hyuntae Kim, Donna L. Coyle
  • Patent number: 9629838
    Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: April 25, 2017
    Assignee: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Zhigang Xiong, Roger P. Simon
  • Patent number: 9522912
    Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (Ia): including stereoisomers and pharmaceutically acceptable salts thereof, wherein A?, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: December 20, 2016
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Elizabeth M. Bacon, Zhenhong R. Cai, Jeromy J. Cottell, Mingzhe Ji, Haolun Jin, Scott E. Lazerwith, Philip Anthony Morganelli, Hyung-jung Pyun
  • Patent number: 9498437
    Abstract: The present invention is directed to an inhalable formulation for the treatment of pulmonary hypertension in a mammal (e.g., humans), wherein the formulation comprises at least one hypertension reducing agent, including but not limited to an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, beta-blocker, calcium-channel blocker or vasodilator, or any combination thereof. The formulations of the present invention may be a solution or suspension, and preferably are suitable for administration via nebulization. The present invention is also directed to a method and kit for treating a mammal suffering from pulmonary hypertension.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: November 22, 2016
    Assignee: Mylan Specialty L.P.
    Inventor: Imtiaz Chaudry
  • Patent number: 9416065
    Abstract: Described herein are compositions comprising an acidifier intermixed with an emulsifier and a co-surfactant that form stable microemulsions in water. Also described are methods of dispersing a compound in an aqueous solution using the compositions of the present invention.
    Type: Grant
    Filed: February 5, 2008
    Date of Patent: August 16, 2016
    Assignee: Archer Daniels Midland Company
    Inventors: Shireen Baseeth, Bruce Sebree
  • Patent number: 9408837
    Abstract: Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are atrisk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: August 9, 2016
    Assignee: Kitov Pharmaceutical Ltd.
    Inventors: Peter C. Hoyle, Paul Waymack
  • Patent number: 9241937
    Abstract: The present disclosure relates to a method of managing urolithiasis or related urological disorders in a subject in need thereof, using pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipient(s).
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: January 26, 2016
    Assignee: INDUS BIOTECH PRIVATE LIMITED
    Inventors: Sunil Bhaskaran, Mohan Vishwaraman
  • Patent number: 9238077
    Abstract: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: January 19, 2016
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Patent number: 9193708
    Abstract: One aspect of the present invention relates to substituted pyridines and pharmaceutially acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: November 24, 2015
    Assignee: Trustees of Tufts College
    Inventors: William W. Bachovchin, Hung-sen Lai
  • Patent number: 9168289
    Abstract: The invention provides a method and a composition for the treatment of infants age less than 2.5 years old defined as small for gestational age (SGA), including the use of hGH or any compound that increases blood levels of hGH or of IGF-I. Early use of the composition prevents the irreversible neurological and psychological damage of the children.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: October 27, 2015
    Assignee: MOR RESEARCH APPLICATIONS LTD.
    Inventor: Zvi Laron
  • Patent number: 9161933
    Abstract: The present invention relates to a solid pharmaceutical composition for preventing or treating cardiovascular disorders comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof, which exhibits high dissolution rates of amlodipine and losartan even under a low pH condition and improved storage stability.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: October 20, 2015
    Assignee: HANMI SCIENCE CO., LTD
    Inventors: Jae Hyun Park, Kyeong Soo Kim, Ho Taek Yim
  • Patent number: 9072732
    Abstract: Niacin prevents and/or reverses the development of experimental hepatic steatosis, deposition of triglycerides in liver and serum of individuals, deposition of total cholesterol in liver and serum in individuals, and inhibit liver lipid peroxidation and oxidative stress in individuals at risk of developing fatty liver disease or NAFLD. In cultured human hepatocytes, niacin inhibits alcohol-induced fat accumulation.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: July 7, 2015
    Assignees: The Regents of the University of California, Veterans Affairs Health Care System
    Inventors: Moti L. Kashyap, Vaijinath S. Kamanna, Shobha V. Kamanna
  • Publication number: 20150139978
    Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.
    Type: Application
    Filed: October 9, 2014
    Publication date: May 21, 2015
    Inventors: Ming-Jen Cheng, Ping-Hsun Yang, Ming-Der Wu, Shie-Jea Lin, Gwo-Fang Yuan, Yen-Lin Chen, Hsuen-Chun Liao, Kai-Ping Chen
  • Publication number: 20150140093
    Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.
    Type: Application
    Filed: November 6, 2014
    Publication date: May 21, 2015
    Inventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
  • Publication number: 20150140113
    Abstract: The present invention generally relates to dosage forms for oral administration including one or more gelling agents. In particular, the present invention is directed to gelling agent-based dosage forms that are easily administered and taken, or swallowed. The present invention is also directed to gelling agent-based dosage forms that exhibit relatively low syneresis, are thermally stable, exhibit substantially constant active ingredient concentration, and/or exhibit one or more advantageous rheological properties. In particular, the present invention is directed to such gels containing one or more omega-3 fatty acids. The gelling agent-based dosage forms of the present invention are suitable for administration of a relatively large dose of active ingredient. The gelling agent-based dosage forms of the present invention are also suitable for administration of multiple active ingredients.
    Type: Application
    Filed: March 19, 2013
    Publication date: May 21, 2015
    Applicant: PARTICLE DYNAMICS INTERNATIONAL, LLC
    Inventors: Irwin Jacobs, Stephen Gee, Paul Brady
  • Publication number: 20150133414
    Abstract: It was determined whether SNPs in SLC4A5 are associated with salt sensitivity of blood pressure (BP). Subjects consumed an isocaloric constant diet with a randomized order of 7 days low Na+ (10 mmol/d) and 7 days high Na+ (300 mmol/d) intake. Salt sensitivity was defined as a ?7 mm Hg increase in mean arterial pressure (MAP). 35 polymorphisms in 17 candidate genes were assayed. Association analyses with salt sensitivity revealed three variants that associated with salt sensitivity, two in SLC4A5 (rs7571842, rs10177833; P<0.001), and one in GRK4 (rs1801058; P=0.020). Paradoxical changes in blood pressure in response to changes in salt intake were also found associated with a SNP for DRD2 (rs6276). In conclusion, SLC4A5 variants are strongly associated with salt sensitivity of BP in Caucasian and a DRD2 SNP is a marker for paradoxical response to salt intake.
    Type: Application
    Filed: April 22, 2013
    Publication date: May 14, 2015
    Applicant: University of Virginia Patent Foundation
    Inventors: Robin A. Felder, Robert M. Carey, John E. Jones, Pedro A. Jose, Scott M. Williams
  • Publication number: 20150132358
    Abstract: A method and apparatus for administering an active agent such as a medicine to a subject, uses an ocular implant such as a punctal plug, to which the active agent has been applied. The implant is installed at the eye of the subject for administering the active agent via tissues of the eye.
    Type: Application
    Filed: August 29, 2014
    Publication date: May 14, 2015
    Inventors: Steven A. Odrich, Liane C. Glazer
  • Publication number: 20150126462
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid, nicotinamide, tryptophanor related compounds for positively influencing the intestinal microbiota. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 7, 2015
    Applicant: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Waetzig, Dirk Seegert
  • Patent number: RE46605
    Abstract: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: November 14, 2017
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Patent number: RE46608
    Abstract: The invention relates to fatty acid niacin conjugates; compositions comprising an effective amount of a fatty acid niacin conjugate; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a fatty acid niacin conjugate.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: November 14, 2017
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu